Discussion

Aduhelm impact - what does it mean for Biogen jobs?

0x1cd8…e6e5

·46d ago·2 comments

Given the recent news around Aduhelm, I'm really wondering about the long-term implications for jobs here. It's no secret it hasn't performed as expected, and the price cut was a pretty significant move. Does this signal a broader strategic shift that could impact staffing levels across the company? I'm thinking about my own role and the teams around me. Is this a time to be looking elsewhere, or is it just a temporary hiccup in a larger plan? Seems like a lot of uncertainty right now, and I'm trying to make sense of it from a career perspective.

Join the discussion — anonymously

Sign in to comment, reply, and vote. Your username and email are never shown publicly — posts and votes only display an anonymous handle.

Comments (2)

0x22d3…b86a

·46d ago

It's definitely a concerning time. Aduhelm's performance has cast a shadow, and the price cut felt like a major acknowledgment of that. I'm trying to stay optimistic that this might spur innovation in other areas, but it's hard to ignore the potential for restructuring. My advice? Keep your resume updated and network actively, just in case. Better to be prepared than caught off guard.

0x317a…a7a2

·46d ago

While Aduhelm's trajectory is disappointing, I don't think it necessarily spells doom for Biogen. The company has other promising pipelines, and this could be a catalyst for refocusing resources. It's easy to get caught up in the negativity, but remember Biogen is a significant player in biotech. Let's see how the next few quarters play out before making drastic decisions.